Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 406-260-5 | CAS number: 58834-75-6 BTN; VPO CATALYST
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Assessed after consultation with the relevant Authority. Data migrated from NONS files provided by Authority contain insufficient information.
Data source
Reference
- Reference Type:
- other: Body responsible for the test
- Title:
- Unnamed
- Report date:
- 1991
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
- GLP compliance:
- yes
- Remarks:
- PHARMACO-LSR LTD. EYE, SUFFOLK IP23 7PX
- Limit test:
- no
Test material
- Reference substance name:
- Vanadyl pyrophosphate
- EC Number:
- 406-260-5
- EC Name:
- Vanadyl pyrophosphate
- Cas Number:
- 58834-75-6
- Molecular formula:
- O9P2V2
- IUPAC Name:
- divanadium(4+) (phosphonatooxy)phosphonate dioxidandiide
- Details on test material:
- - Name of test material (as cited in study report): BTN/A
- Analytical purity: no data
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Crj: CD(SD)
- Sex:
- male/female
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: 1.0% w/v methylcellulose in distilled water.
- Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- Test duration: 28 days
- Frequency of treatment:
- Dosing regime: 7 days/week
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0, 40, 200, 1000 mg/kg bw
Basis:
no data
- No. of animals per sex per dose:
- 6
- Control animals:
- yes, concurrent vehicle
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Mortality:
- mortality observed, treatment-related
- Body weight and weight changes:
- effects observed, treatment-related
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, treatment-related
- Clinical biochemistry findings:
- effects observed, treatment-related
- Urinalysis findings:
- effects observed, treatment-related
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- effects observed, treatment-related
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- CLINICAL SIGNS, BODY WEIGHT AND MORTALITY
No signs of reaction to BTN/A were observed in males treated at 1000 mg/kg/day, or in animals treated at 40 or 200 mg/kg/day. Four females receiving 1000 mg/kg/day died during the study; ante mortem signs included underactivity, reduced body temperature, thin and ungroomed appearance, bodyweight loss, hunched posture and loose faeces.
HAEMATOLOGY
Packed cell volume, haemoglobin concentration, mean cell volume and mean cell haemoglobin of male rats treated at 1000 mg/kg/day were marginally lower than those of the male controls. The neutrophil and eosinophil counts of one female surviving treatment at 1000 mg/kg/day were considerably higher than the counts recorded for the female control animals.
CLINICAL CHEMISTRY
Slightly low plasma alkaline phosphatase and slightly high alanine amino-transferase activities were recorded for rats treated at 1000 mg/kg/day, when compared with those of the control animals. The plasma albumin and total protein concentrations of male rats treated at 1000 mg/kg/day were marginally lower than those of the male controls. A reduced beta-globulin concentration and a correspondingly raised albumin: globulin ratio were recorded for the two surviving female rats treated at 1000 mg/kg/day.
URINALYSIS
Slightly lower urinary volume and pH, slightly higher specific gravity and protein concentration and increased epithelial cell populations for surviving female rats treated at 1000 mg/kg/day compared to the female controls. Slightly lower urinary pH was also recorded for male rats treated at this level,when compared with the male controls.
EFFECTS IN ORGANS and GROSS PATHOLOGY
There were no changes in the organs of animals surviving to termination which were attributed to BTN/A treatment.
Abnormal gastro-intestinal tract contents and emaciation were recorded for three of the four decedent females that received BTN/A at 1000 mg/kg/day: all four showed atrophy of the white pulp of the spleen and glycogen depletion of the liver. These non-specific findings were attributed to the poorconditions of the animals and not specifically to treatment with BTN/A.
Effect levels
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- 200 mg/kg bw/day (nominal)
- Sex:
- not specified
- Basis for effect level:
- other: original NCD unit is mg/kg/day.
- Dose descriptor:
- NOEL
- Effect level:
- 200 mg/kg bw/day (nominal)
- Sex:
- not specified
- Basis for effect level:
- other: original NCD unit is mg/kg/day.
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- DSD: not classified
CLP: not classified
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.